To overcome this limitation, GLP-1 receptor agonists (GLP-1 RAs) have been developed to provide prolonged receptor activation and are now widely used for managing metabolic diseases, including obesity (Drucker, 2022; Zheng et al., 2024). This evidence concerns the gene GCG and obesity disorder.